Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Benefits and risks of zinc for adults during covid-19: rapid systematic review and meta-analysis of randomised controlled trials

View ORCID ProfileJennifer Hunter, View ORCID ProfileSusan Arentz, View ORCID ProfileJoshua Goldenberg, View ORCID ProfileGuoyan Yang, View ORCID ProfileJennifer Beardsley, View ORCID ProfileStephen P Myers, View ORCID ProfileDominik Mertz, View ORCID ProfileStephen Leeder
doi: https://doi.org/10.1101/2020.11.02.20220038
Jennifer Hunter
1NICM Health Research Institute, Western Sydney University, Penrith, NSW, 2751, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jennifer Hunter
  • For correspondence: jennifer.hunter@westernsydney.edu.au
Susan Arentz
1NICM Health Research Institute, Western Sydney University, Penrith, NSW, 2751, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Susan Arentz
Joshua Goldenberg
2Helfgott Research Institute, National University of Natural Medicine, Portland, OR, 97201, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Joshua Goldenberg
Guoyan Yang
1NICM Health Research Institute, Western Sydney University, Penrith, NSW, 2751, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Guoyan Yang
Jennifer Beardsley
3Independent Librarian, Seattle, WA 98115, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jennifer Beardsley
Stephen P Myers
4NatMed Research Unit, Southern Cross University, Lismore, NSW, 2480, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Stephen P Myers
Dominik Mertz
5Division of Infectious Diseases, Department of Medicine, Health Sciences, McMaster University, Hamilton, Ontario, L8N 3Z5, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Dominik Mertz
Stephen Leeder
6Menzies Centre for Health Policy, Sydney School of Public Health, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, 2006, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Stephen Leeder
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Objective To evaluate the benefits and risks of any type of zinc intervention to prevent or treat SARS-CoV-2.

Design A living, systematic review and meta-analysis, incorporating rapid review methods.

Data sources 17 English and Chinese databases and clinical trial registries were searched in April/May 2020, with additional covid-19 focused searches in June and August 2020.

Eligibilitycriteria and analysis Randomized control trials (RCTs) published in any language comparing zinc to a control to prevent or treat SARS-CoV-2. Other viral respiratory tract infections (RTIs) were included, but the certainty of evidence downgraded twice for indirectness. Screening, data extraction, risk of bias appraisal (RoB-2 tool) and verification was performed by calibrated, single reviewers. RCTs with adult populations were prioritised for analysis.

Results 123 RCTs were identified. None were specific to SARS-CoV-2 nor other coronaviruses. 28 RCTs evaluated oral (15-45mg daily), sublingual (45-300mg daily), or topical nasal (0.09-2.6 mg daily) zinc to prevent or treat nonspecific viral RTIs in 3,597 adults without zinc deficiency. Compared to placebo, zinc prevented 5 mild to moderate RTIs per 100 person-months, including in older adults (95% confidence interval 1 to 9) (number needed to treat (NTT)=20). There was no significant difference in the rates of non-serious adverse events (AE). For RTI treatment, a clinically important reduction in peak symptom severity scores was found for zinc compared to placebo (mean difference 1.2 points, 0.7 to 1.7), but not average daily symptom severity (standardised mean difference 0.2, 0.1 to 0.4). 19 fewer per 100 adults were at risk of remaining symptomatic over the first 7 days (2 to 38, NNT=5) and the mean duration of symptoms was 2 days shorter (0.2 to 3.5), however, there was substantial heterogeneity (I2 = 82% and 97%). 14 more per 100 experienced a non-serious AE (4 to 16, NNT=7) such as nausea, or mouth or nasal irritation. No differences in illness duration nor AE were found when zinc was compared to active controls. No serious AE, including copper deficiency, were reported by any RCT. Quality of life outcomes were not assessed. Confidence in these findings for SARS-CoV-2 is very low due to serious indirectness and some concerns about bias for most outcomes.

Conclusions Zinc is a potential therapeutic candidate for preventing and treating SARS-CoV-2, including older adults and adults without zinc deficiency (very low certainty). Zinc may also help to prevent other viral RTIs during the pandemic (moderate certainty) and reduce the severity and duration of symptoms (very low certainty). The pending results from seven RCTs evaluating zinc for SARS-CoV-2 will be tracked.

Systematic review registration PROSPERO CRD42020182044

Competing Interest Statement

All authors have completed the Unified Competing Interest form (available on request from the corresponding author) and declare: no support from any organisation for the submitted work. Authors DM and SL have no financial relationships with any organisations that might have an interest in the submitted work in the previous three years and no other relationships or activities that could appear to have influenced the submitted work. Authors SA, JH and GY are academic researchers at NICM Health Research Institute. As a medical research institute, NICM Health Research Institute receives research grants and donations from foundations, universities, government agencies, individuals, and industry. Sponsors and donors provide untied funding for work to advance the vision and mission of the Institute. This review was not undertaken as part of a contractual relationship with any donor or sponsor. JH is an academic general practitioner with a clinical interest in integrative medicine, has received payment for providing expert advice about traditional, complementary and integrative medicine, including nutraceuticals, to industry, government bodies and non-government organisations, and spoken at workshops, seminars and conferences for which registration, travel and/or accommodation has been paid for by the organisers. SA is a naturopathic practitioner at an obstetrics and gynaecology clinic in Sydney, Australia. She has received payment for providing expert editing of naturopathic and herbal medicine educational programs, and for investigation of naturopathy, herbal medicines and nutraceuticals in clinical trials and spoken at workshops, seminars and conferences for which registration, travel and/or accommodation has been paid by the organisers. GY is an academic researcher with interest in complementary and integrative medicine. She has spoken at research workshops, seminars and conferences for which registration and travel has been paid by the organisers. JG is a naturopathic doctor and director of a functional bowel disease clinic in Colorado Springs, USA. JG has spoken at research conferences for which registration, travel and/or accommodation has been paid by the organisers. He is also a research investigator at the Helfgott Research Institute, National University of Natural Medicine. As a medical research institute, Helfgott receives research grants and untied donations from foundations, universities, government agencies, individuals and industry. This review was not undertaken as part of a contractual relationship with any donor or sponsor. JB is an independent librarian and reports personal fees from Helfgott Research Institute, National University of Natural Medicine, during the conduct of the study. SM is an academic researcher at Southern Cross University where he is Director of the NatMed Research Unit. NatMed Institute receives research grants individuals, and industry. This review was not undertaken as part of a contractual relationship with any donor or sponsor. SM is a research academic in traditional, complementary and integrative medicine, and has received payment for providing expert advice to industry, government bodies and non-government organisations, and spoken at workshops, seminars and conferences for which registration, travel and/or accommodation has been paid for by the organisers.

Clinical Protocols

https://doi.org/10.1016/j.imr.2020.100457

https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020182044

Funding Statement

No external funding was received

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

not applicable

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Additional data is available upon reasonable request to the authors

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Back to top
PreviousNext
Posted November 04, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Benefits and risks of zinc for adults during covid-19: rapid systematic review and meta-analysis of randomised controlled trials
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Benefits and risks of zinc for adults during covid-19: rapid systematic review and meta-analysis of randomised controlled trials
Jennifer Hunter, Susan Arentz, Joshua Goldenberg, Guoyan Yang, Jennifer Beardsley, Stephen P Myers, Dominik Mertz, Stephen Leeder
medRxiv 2020.11.02.20220038; doi: https://doi.org/10.1101/2020.11.02.20220038
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Benefits and risks of zinc for adults during covid-19: rapid systematic review and meta-analysis of randomised controlled trials
Jennifer Hunter, Susan Arentz, Joshua Goldenberg, Guoyan Yang, Jennifer Beardsley, Stephen P Myers, Dominik Mertz, Stephen Leeder
medRxiv 2020.11.02.20220038; doi: https://doi.org/10.1101/2020.11.02.20220038

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (70)
  • Allergy and Immunology (169)
  • Anesthesia (51)
  • Cardiovascular Medicine (455)
  • Dentistry and Oral Medicine (83)
  • Dermatology (55)
  • Emergency Medicine (160)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (192)
  • Epidemiology (5300)
  • Forensic Medicine (3)
  • Gastroenterology (198)
  • Genetic and Genomic Medicine (762)
  • Geriatric Medicine (81)
  • Health Economics (214)
  • Health Informatics (703)
  • Health Policy (363)
  • Health Systems and Quality Improvement (224)
  • Hematology (100)
  • HIV/AIDS (165)
  • Infectious Diseases (except HIV/AIDS) (5945)
  • Intensive Care and Critical Care Medicine (368)
  • Medical Education (105)
  • Medical Ethics (25)
  • Nephrology (83)
  • Neurology (777)
  • Nursing (43)
  • Nutrition (135)
  • Obstetrics and Gynecology (146)
  • Occupational and Environmental Health (236)
  • Oncology (481)
  • Ophthalmology (154)
  • Orthopedics (40)
  • Otolaryngology (97)
  • Pain Medicine (39)
  • Palliative Medicine (20)
  • Pathology (141)
  • Pediatrics (223)
  • Pharmacology and Therapeutics (138)
  • Primary Care Research (99)
  • Psychiatry and Clinical Psychology (866)
  • Public and Global Health (2041)
  • Radiology and Imaging (355)
  • Rehabilitation Medicine and Physical Therapy (160)
  • Respiratory Medicine (287)
  • Rheumatology (95)
  • Sexual and Reproductive Health (74)
  • Sports Medicine (77)
  • Surgery (110)
  • Toxicology (25)
  • Transplantation (29)
  • Urology (39)